Payment overview · 2025
General Payments
$399.19
13 reported records · 10 companies
Healthcare provider profile · identity verified
Kimberly S Evans, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALBANY, KY · NPI 1326492919
Verified facts
What the public records show
CMS Open Payments records show Kimberly S Evans, APRN received $399.19 in general payments during 2025 across 13 reported records.
Medtronic, Inc. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$125.05 | 31.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $82.26 | 20.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.87 | 10.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.22 | 7.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.88 | 7.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.10 | 6.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.01 | 5.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $19.77 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.14 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.89 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.19 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $125.05 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $82.26 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 48 |
| Lisinopril | Lisinopril | 237 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 26 |
| Omeprazole | Omeprazole | 173 | 29 |
| Gabapentin | Gabapentin | 169 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 34 |
| Metformin Hcl | Metformin Hcl | 136 | 20 |
| Furosemide | Furosemide | 128 | 28 |
| Azithromycin | Azithromycin | 121 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 117 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 15 |
| Prednisone | Prednisone | 110 | 66 |
| Montelukast Sodium | Montelukast Sodium | 101 | 13 |
| Simvastatin | Simvastatin | 101 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 13 |
| Meloxicam | Meloxicam | 98 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 19 |
| Sertraline Hcl | Sertraline Hcl | 79 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 66 | 24 |
| Atenolol | Atenolol | 64 | suppressed |
| Potassium Chloride | Potassium Chloride | 64 | 12 |
| Tramadol Hcl | Tramadol Hcl | 61 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 25 |
| Losartan Potassium | Losartan Potassium | 56 | 12 |
| Ozempic | Semaglutide | 56 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | suppressed |
| Eliquis | Apixaban | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Carvedilol | Carvedilol | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 30 |
| Ibuprofen | Ibuprofen | 39 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Dexamethasone | Dexamethasone | 21 | 20 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Allopurinol | Allopurinol | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.19 · 13 records | Medtronic, Inc. | BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, INCEPTIV, INGREZZA, NURTEC ODT, Polivy, The Cologuard Plus Collection Kit, VRAYLAR, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error